CXCL13 and myeloid sarcoma: Subsequent categorical testing against the other biomarkers, clinical and paraclinical parameters still showed highly significant relations between CXCL13, MMP-9 and CXCL10 (p<0.0001 for all) and between CXCL13, MMP-9 and all CSF MS-risk parameters (p<0.0001 for all).